HHS Secretary Leavitt Calls For “Explicit Extraterritorial Jurisdiction” For U.S. FDA
This article was originally published in PharmAsia News
Executive Summary
U.S. Health and Human Services Secretary Michael Leavitt requested Congress in a Feb. 22 letter to grant FDA "explicit extraterritorial jurisdiction" to investigate manufacturers whose products are subject to the Federal Food, Drug, and Cosmetic Act
You may also be interested in...
Contaminant Discovered In Chinese-Produced Heparin API
U.S FDA has discovered "significant quantities" of a heparin-like contaminant in tested samples of heparin API manufactured by Baxter-supplier Scientific Protein Laboratories' Changzhou plant
Contaminant Discovered In Chinese-Produced Heparin API
U.S FDA has discovered "significant quantities" of a heparin-like contaminant in tested samples of heparin API manufactured by Baxter-supplier Scientific Protein Laboratories' Changzhou plant
Baxter’s Chinese API Supplier Cited For “Objectionable Practices;” Remaining Heparin Vials Recalled
U.S. FDA has issued a Form 483 to Changzhou SPL, Baxter Healthcare's heparin API supplier, after inspecting the Changzhou City plant, FDA announced Feb. 28 during an update of the agency's ongoing investigation of Baxter's heparin products